

Thermo Fisher signs CDx agreement with Chugai Pharma

09 July 2020 | News

Agreement aims to expedite local biomarker testing of NSCLC patients eligible for entrectinib in Japan



Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Japan based Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and has applied to the Ministry of Health, Labour and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test in Japan.

The CDx will be leveraged to identify ROS1-positive non-small cell lung cancer (NSCLC) patients who may be eligible for treatment with entrectinib (Rozlytrek).

Approval by the MHLW would accelerate access to Chugai's targeted therapy via a locally administered, next-generation sequencing (NGS) biomarker test.

Oncomine Dx Target Test is currently reimbursed by government and commercial insurers in the U.S., Europe, Japan and South Korea, covering more than 550 million lives globally.